Keros Therapeutics (NASDAQ:KROS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday, Zacks.com reports.
According to Zacks, “Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company’s product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA. “
NASDAQ:KROS traded up $0.03 on Friday, reaching $52.09. 100,930 shares of the company’s stock were exchanged, compared to its average volume of 117,460. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -19.22 and a beta of 1.52. The business has a fifty day moving average of $51.76 and a 200-day moving average of $45.41. Keros Therapeutics has a 52-week low of $28.50 and a 52-week high of $71.74.
In other Keros Therapeutics news, insider Jennifer Lachey sold 735 shares of the firm’s stock in a transaction dated Wednesday, December 15th. The stock was sold at an average price of $50.00, for a total value of $36,750.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Julius Knowles sold 23,555 shares of Keros Therapeutics stock in a transaction dated Monday, January 3rd. The shares were sold at an average price of $58.01, for a total value of $1,366,425.55. The disclosure for this sale can be found here. Insiders sold 38,189 shares of company stock valued at $2,174,356 over the last three months. Corporate insiders own 36.10% of the company’s stock.
A number of hedge funds have recently bought and sold shares of KROS. Nisa Investment Advisors LLC acquired a new position in Keros Therapeutics during the 4th quarter worth $40,000. Royal Bank of Canada raised its holdings in Keros Therapeutics by 22.6% in the 3rd quarter. Royal Bank of Canada now owns 1,433 shares of the company’s stock valued at $57,000 after acquiring an additional 264 shares in the last quarter. Macquarie Group Ltd. raised its holdings in Keros Therapeutics by 548.8% in the 3rd quarter. Macquarie Group Ltd. now owns 1,622 shares of the company’s stock valued at $64,000 after acquiring an additional 1,372 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in shares of Keros Therapeutics in the 4th quarter worth approximately $139,000. Finally, Arizona State Retirement System acquired a new position in shares of Keros Therapeutics in the 4th quarter worth approximately $202,000. Institutional investors own 64.65% of the company’s stock.
About Keros Therapeutics
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
